Denali Therapeutics (DNLI) Receivables - Net (2018 - 2026)

Denali Therapeutics (DNLI) has reported Receivables - Net for 9 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net fell 5.88% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $1.6 million (down 5.88% YoY), while the FY2025 annual figure was $2.2 million, changed 0.28% from the prior year.
• Receivables - Net steadied at $1.6 million in Q1 2026 per DNLI's latest filing, from $1.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $9.3 million in Q4 2022 and bottomed at $1.4 million in Q2 2024.
• Historically, Receivables - Net has averaged $2.6 million across 5 years, with a median of $1.9 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables - Net slumped 70.91% — and 2025, when it jumped 35.71%.
• Denali Therapeutics' Receivables - Net stood at $9.3 million in 2022, then plunged by 70.91% to $2.7 million in 2023, then retreated by 19.59% to $2.2 million in 2024, then declined by 26.3% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
• Business Quant data shows DNLI's Receivables - Net at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.9 million in Q3 2025.